Giving Life To Muscles

FSHD Global joins landmark international collaboration to accelerate FSHD treatments

FSHD Global commits more than $800,000 to a global effort to develop faster, smarter and less invasive clinical trials for people living with FSHD

FSHD Global Research Foundation has joined a major international collaboration bringing together leading FSHD organisations, researchers, biotechnology companies and technology partners to tackle some of the biggest shared challenges in developing treatments for facioscapulohumeral muscular dystrophy (FSHD).

As a new member of the FSHD Industry Collaborative, FSHD Global has committed USD $582,285 — more than AUD $800,000 — to the partnership, a large percentage of which is direct funding for an advanced MRI research program.

FSHD Global will also join the leadership of the Collaborative alongside the FSHD Society, SOLVE FSHD, FSHD Clinical Trial Research Network (FSHD CTRN), and Global FSHD Innovation Hub.

Launched in April 2026, the Collaborative is a pre-competitive international initiative bringing patient organisations, clinical and academic experts, technology partners, and companies developing FSHD therapies together to address research and development challenges shared across the field.

FSHD Global’s contribution builds on years of work to advance whole-body MRI in FSHD, including funding foundational research to validate technology developed by Springbok Analytics to quantify changes in individual muscles, and helping to fund Springbok’s development of a full body muscle atlas and an AI-powered FSHD disease progression model to predict future changes in muscle.

These capabilities can now be applied to major clinical trial datasets through the Collaborative, alongside emerging biomarkers and functional measures, to strengthen the design and evaluation of future FSHD trials.

“FSHD Global has strategically supported the advancement of MRI and disease modelling to improve how we measure and predict FSHD progression. Through the Industry Collaborative, these capabilities can now be combined with international expertise and major clinical trial datasets to generate evidence that can strengthen clinical development across the FSHD therapeutic pipeline,” said Emma Weatherley, Managing Director of FSHD Global.

Honouring patient contributions by giving clinical trial data a new purpose

A major focus of FSHD Global’s support will be analysis of whole-body MRI data generated by people living with FSHD who participated in Fulcrum Therapeutics’ Phase II and Phase III losmapimod trials.

While the treatment program was discontinued, participants gave their time and underwent extensive testing in the hope of advancing FSHD treatments. Through the Industry Collaborative, their contribution can continue to benefit the field.

Springbok will apply its advanced muscle analytics to the MRI data to better understand which muscles are most likely to change during a clinical trial and how those changes relate to biomarkers and functional outcomes, helping ensure the right measures are selected for future trials.

“While the trial did not deliver the treatment outcome hoped for, the contribution of those patients was highly valuable. We now have an opportunity to ensure the data collected during their participation helps give future FSHD trials a better chance of success,” Weatherley said.

Father and daughter, Mark and Zaharrah Priestley, are facing FSHD together

Building better and less invasive clinical trials

Measuring whether a treatment is working is particularly challenging in FSHD because progression varies significantly between individuals and between different muscles within the same person.

Advanced whole-body MRI provides an opportunity to objectively quantify changes across many muscles without an invasive procedure or risk of radiation. Combined with emerging blood-based molecular biomarkers and predictive disease modelling, these tools could provide more sensitive ways to determine whether a therapy is changing the course of FSHD and, ultimately, reduce reliance on invasive muscle biopsies.

The Collaborative will investigate relationships between MRI, molecular biomarkers, functional assessments and patient-reported outcomes to build a more comprehensive picture of disease progression and treatment response. Its broader priorities include developing clinically qualified and regulatory-ready biomarker assays and improving patient selection and clinical trial design.

By bringing these activities together within a pre-competitive model, data, technology and expertise can be shared across stakeholders rather than developed independently for individual drugs or companies.

For FSHD Global, the partnership represents an exciting opportunity to leverage fund provided over many years and put the resulting tools to work on an international scale — supporting the development of multiple potential FSHD therapies.

About the FSHD Industry Collaborative

The FSHD Industry Collaborative is a pre-competitive international network established to accelerate therapeutic development for FSHD.

Jointly led by the FSHD Society, SOLVE FSHD, the FSHD Clinical Trial Research Network and FSHD Global Research Foundation, the Collaborative brings together patient organisations, pharmaceutical and biotechnology companies, academic clinicians and scientists, key opinion leaders and technology partners to address shared research and development gaps.

Through shared research, data and expertise, the Collaborative aims to generate and validate tools that can improve clinical trial design, reduce development risk and accelerate the path towards effective treatments for people living with FSHD.

Scroll to Top